Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
15.55
+0.02 (0.13%)
At close: Jun 6, 2025, 4:00 PM
15.55
0.00 (0.00%)
After-hours: Jun 6, 2025, 7:00 PM EDT
Dr. Reddy's Laboratories Revenue
In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B INR with 16.61% growth. Dr. Reddy's Laboratories had revenue of 85.06B in the quarter ending March 31, 2025, with 20.09% growth.
Revenue (ttm)
325.54B INR
Revenue Growth
+16.61%
P/S Ratio
3.37
Revenue / Employee
12,035,455 INR
Employees
27,048
Market Cap
12.82B USD
Revenue Chart
* This company reports financials in INR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
RDY News
- 1 day ago - Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug - Benzinga
- 1 day ago - Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) - Business Wire
- 22 days ago - Dr. Reddy's Continues To Be A Good Buy At Current Valuation - Seeking Alpha
- 4 weeks ago - Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Dr. Reddy's Q4 & Full Year FY25 Financial Results - Business Wire
- 2 months ago - Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out - Seeking Alpha
- 2 months ago - Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia - PRNewsWire
- 2 months ago - Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® - Business Wire